Shield Therapeutics (LSE:STX) EV-to-Revenue : 0.28 (As of Apr. 26, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Shield Therapeutics's enterprise value is £1.76 Mil. Shield Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was £6.19 Mil. Therefore, Shield Therapeutics's EV-to-Revenue for today is 0.28.

The historical rank and industry rank for Shield Therapeutics's EV-to-Revenue or its related term are showing as below:

LSE:STX' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.36 Med: 12.06 Max: 491.7
Current: 0.28

During the past 9 years, the highest EV-to-Revenue of Shield Therapeutics was 491.70. The lowest was -0.36. And the median was 12.06.

LSE:STX's EV-to-Revenue is ranked better than
95.81% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs LSE:STX: 0.28

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Shield Therapeutics's stock price is £0.01225. Shield Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was £0.01. Therefore, Shield Therapeutics's PS Ratio for today is 0.94.

Shield Therapeutics EV-to-Revenue Historical Data

The historical data trend for Shield Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics EV-to-Revenue Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

Get a 7-Day Free Trial

2.18

286.02

6.91

55.37

4.83

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-Revenue	Get a 7-Day Free Trial													-	55.37	-	4.83	-

Competitive Comparison of Shield Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's EV-to-Revenue falls into.

Shield Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Shield Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1.758	/	6.187
	=	0.28

Shield Therapeutics's current Enterprise Value is £1.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was £6.19 Mil.

Shield Therapeutics (LSE:STX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Shield Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.01225	/	0.013
	=	0.94

Shield Therapeutics's share price for today is £0.01225.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was £0.01.

Shield Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.